Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIG1 | P18858 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | FABP3 | P05413 | 2/20 | 0.47 |
| ▸ | FABP4 | P15090 | 2/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7634575 | 0.90 | TSHR (0.51) | LIG1TSHRGAASMN1; SMN2NPC1 | |
| SCHEMBL668774 | 0.89 | SMN1; SMN2 (0.58) | LIG1TSHRGAASMN1; SMN2NPC1 | |
| SCHEMBL5243985 | 0.89 | LIG1 (0.48) | LIG1TSHRGAASMN1; SMN2NPC1 | |
| SCHEMBL5239239 | 0.87 | MAPK1 (0.66) | LIG1TSHRGAASMN1; SMN2NPC1 | |
| SCHEMBL3944765 | 0.86 | LIG1 (0.54) | LIG1TSHRGAASMN1; SMN2NPC1 | |
| SCHEMBL13400836 | 0.86 | LIG1 (0.54) | LIG1TSHRGAASMN1; SMN2NPC1 | |
| SCHEMBL31311029 | 0.86 | LIG1 (0.48) | LIG1TSHRGAASMN1; SMN2NPC1 | |
| SCHEMBL27051428 | 0.86 | LIG1 (0.45) | LIG1TSHRGAASMN1; SMN2NPC1 | |
| SCHEMBL2470333 | 0.85 | LIG1 (0.54) | LIG1TSHRGAASMN1; SMN2NPC1 | |
| SCHEMBL40310 | 0.85 | LIG1 (0.69) | LIG1TSHRGAAHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014891-B2 | Reduction-triggered antibacterial sideromycins | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-05-25 | — | — | US | disclosed |
| US-9623127-B2 | Multimodal contrast and radiopharmaceutical agent for an imaging and a targeted therapy guided by imaging | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-04-18 | — | — | US | disclosed |
| US-9623127-B2 | Multimodal contrast and radiopharmaceutical agent for an imaging and a targeted therapy guided by imaging | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-04-18 | — | — | US | disclosed |
| US-20160368878-A1 | REDUCTION-TRIGGERED ANTIBACTERIAL SIDEROMYCINS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-22 | — | — | US | disclosed |
| WO-2015061630-A2 | REDUCTION-TRIGGERED ANTIBACTERIAL SIDEROMYCINS | MILLER MARVIN J (US) | 2015-04-30 | — | — | WO | disclosed |
| US-20140336368-A1 | MULTIMODAL CONTRAST AND RADIOPHARMACEUTICAL AGENT FOR AN IMAGING AND A TARGETED THERAPY GUIDED BY IMAGING | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-11-13 | — | — | US | disclosed |
| US-20140336368-A1 | MULTIMODAL CONTRAST AND RADIOPHARMACEUTICAL AGENT FOR AN IMAGING AND A TARGETED THERAPY GUIDED BY IMAGING | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-11-13 | — | — | US | disclosed |
| US-5073448-A | Containing light stabilizers | CIBA-GEIGY CORPORATION (US) | 1991-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014891-B2 | Reduction-triggered antibacterial sideromycins | HAMP, SLC40A1, FTH1 | LIG1 1509/4885TSHR 1637/4885GAA 2127/4885 |
| US-20160368878-A1 | REDUCTION-TRIGGERED ANTIBACTERIAL SIDEROMYCINS | HAMP, SLC40A1, FTH1 | LIG1 1509/4885TSHR 1637/4885GAA 2127/4885 |
| US-20140336368-A1 | MULTIMODAL CONTRAST AND RADIOPHARMACEUTICAL AGENT FOR AN IMAGING AND A TARGETED THERAPY GUIDED BY IMAGING | RXFP1, SSTR4, MEN1 | LIG1 2790/4885TSHR 446/4885GAA 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.